Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies called checkpoint inhibitors. A study from Georgia Tech and Emory University researchers is offering an improved understanding of why these inhibitors work—and how to make them effectively fight cancer for more patients.
